GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (LSE:DDDD) » Definitions » Additional Paid-In Capital

4d pharma (LSE:DDDD) Additional Paid-In Capital : £185.70 Mil(As of Dec. 2021)


View and export this data going back to 2014. Start your Free Trial

What is 4d pharma Additional Paid-In Capital?


4d pharma's quarterly additional paid-in capital increased from Dec. 2020 (£136.28 Mil) to Jun. 2021 (£185.67 Mil) and increased from Jun. 2021 (£185.67 Mil) to Dec. 2021 (£185.70 Mil).

4d pharma's annual additional paid-in capital increased from Dec. 2019 (£132.99 Mil) to Dec. 2020 (£136.28 Mil) and increased from Dec. 2020 (£136.28 Mil) to Dec. 2021 (£185.70 Mil).


4d pharma Additional Paid-In Capital Historical Data

The historical data trend for 4d pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Additional Paid-In Capital Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Additional Paid-In Capital
Get a 7-Day Free Trial 108.30 108.30 132.99 136.28 185.70

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.99 130.19 136.28 185.67 185.70

4d pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

4d pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of 4d pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma (LSE:DDDD) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (LSE:DDDD) Headlines

No Headlines